Schoumacher, Marie <br/><br/>
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.  [electronic resource] 

 -  Cancer research  Jun 2014 
 - 3294-305 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-14-0138-T  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetamides--administration & dosage<br/>Aminopyridines--administration & dosage<br/>Aniline Compounds--administration & dosage<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Erlotinib Hydrochloride<br/>Feedback, Physiological<br/>Female<br/>Humans<br/>MAP Kinase Kinase Kinases--antagonists & inhibitors<br/>Mice<br/>Mice, Nude<br/>Morpholines--administration & dosage<br/>Mutation<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Pyrimidinones--administration & dosage<br/>Quinazolines--administration & dosage<br/>Receptor, Fibroblast Growth Factor, Type 2--antagonists & inhibitors<br/>Signal Transduction<br/>Sulfonamides--administration & dosage<br/>Tankyrases--antagonists & inhibitors<br/>Thiazoles--administration & dosage<br/>Xenograft Model Antitumor Assays<br/>ras Proteins--genetics